RT Journal Article
T1 Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
A1 Paiva, Bruno
A1 Puig, Noemi
A1 Cedena, Maria-Teresa
A1 Rosiñol, Laura
A1 Cordón, Lourdes
A1 Vidriales, María-Belén
A1 Burgos, Leire
A1 Flores-Montero, Juan
A1 Sanoja-Flores, Luzalba
A1 Lopez-Anglada, Lucia
A1 Maldonado, Roberto
A1 de la Cruz, Javier
A1 Gutierrez, Norma C
A1 Calasanz, Maria-Jose
A1 Martin-Ramos, Maria-Luisa
A1 Garcia-Sanz, Ramón
A1 Martinez-Lopez, Joaquin
A1 Oriol, Albert
A1 Blanchard, María-Jesús
A1 Rios, Rafael
A1 Martin, Jesus
A1 Martinez-Martinez, Rafael
A1 Sureda, Anna
A1 Hernandez, Miguel-Teodoro
A1 de la Rubia, Javier
A1 Krsnik, Isabel
A1 Moraleda, Jose-Maria
A1 Palomera, Luis
A1 Bargay, Joan
A1 Van Dongen, Jacques J M
A1 Orfao, Alberto
A1 Mateos, Maria-Victoria
A1 Blade, Joan
A1 San-Miguel, Jesús F
A1 Lahuerta, Juan-José
A1 GEM (Grupo Español de Mieloma)/PETHEMA (Programa Para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group, 
AB Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG). In the PETHEMA/GEM2012MENOS65 trial, 458 patients with newly diagnosed MM had longitudinal assessment of MRD after six induction cycles with bortezomib, lenalidomide, and dexamethasone (VRD), autologous transplantation, and two consolidation courses with VRD. MRD was assessed in 1,100 bone marrow samples from 397 patients; the 61 patients without MRD data discontinued treatment during induction and were considered MRD positive for intent-to-treat analysis. The median limit of detection achieved by NGF was 2.9 × 10-6. Patients received maintenance (lenalidomide ± ixazomib) according to the companion PETHEMA/GEM2014MAIN trial. Overall, 205 (45%) of 458 patients had undetectable MRD after consolidation, and only 14 of them (7%) have experienced progression thus far; seven of these 14 displayed extraosseous plasmacytomas at diagnosis and/or relapse. Using time-dependent analysis, patients with undetectable MRD had an 82% reduction in the risk of progression or death (hazard ratio, 0.18; 95% CI, 0.11 to 0.30; P  The IMWG flow MRD-negative response criterion is highly applicable and sensitive to evaluate treatment efficacy in MM.
YR 2019
FD 2019-11-26
LK http://hdl.handle.net/10668/14743
UL http://hdl.handle.net/10668/14743
LA en
DS RISalud
RD Apr 8, 2025